Inflammatory Diseases


Image
Naïve, protein-naïve and non-naïve study subjects.
Image
Acute, short-infusion or repeated dosing designs.
Image
General, tissue and cell-specific inflammatory evaluations.
Image
Full clinical chemistry, clinical pathology and clinical toxicology support.
Image
Tissue-specific safety biomarker levels by biosampling, biopsy or microdialysis.
Image
Organ-specific or complete histology and pathology evaluation.

Extensive inflammation models in cynomolgus and marmosets with functional and clinical assessments:

  • Dermal inflammation: DI
  • Irritable bowel diseases: IBD
  • Multiple sclerosis: MS
  • Respiratory/asthma/COPD: RAC
  • Sepsis/ endotoxemia: ET
  • Wound healing: WH

Comprehensive inflammation biomarkers assays:

  • Standard and expanded multiplexed cytokine assays
  • Immune markers (comprehensive CD markers panels by flow cytometry)
  • Acute phase proteins assays (CRP and SAA)
  • Cellular lipid markers assays